References

I-58

1. Toscano A, Schoser B. Enzyme replacement therapy in late-onset Pompe disease: A systematic literature review. *J Neurol.* 2013;260:951–959.

2. Vianello A, Semplicini C, Paladini L, et al. Enzyme replacement therapy improves respiratory outcomes in patients with late-onset type II glycogenosis and high ventilator dependency. *Lung*. 2013;191:537–544.

3. Hamoud H, Khallaf A, Propst J. CRIM-negative Pompe disease patients with satisfactory clinical outcomes on enzyme replacement therapy. *JIMD Rep.* 2013;9:133-137.

4. Fuller D, ElMallah MK, Smith B, et al. The respiratory neuromuscular system in Pompe disease. *Respir Physiol Neurobiol*. 2013;189(2):241-249.

5. Doerfler P, Nayak S, Corti M, et al. Targeted approaches to induce immune tolerance for Pompe disease therapy. *Mol Ther Methods Clin Dev*. 2016;3:15053.

6. Milligan A, Hughes D, Goodwin S, et al. Intravenous enzyme replacement therapy: better in home or hospital? *Brit J Nurs.* 2006;330-333.

7. Hughes DA, Milligan A, Mehta A. Home therapy for lysosomal storage disorders. *Brit J Nurs.* 2007; 1384-1389.

8. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. *Healthcare*. 2016.

9. ASHP Guidelines on Home Infusion Pharmacy Services, 2013.

10. MICROMEDEX®SOLUTIONS Compendia. 2017. Alglucosidase alfa.

11. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Alglucosidase alfa.